Integra LifeSciences Holdings (IART) Stock Overview
Manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
IART Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Integra LifeSciences Holdings Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.76 |
| 52 Week High | US$18.90 |
| 52 Week Low | US$8.70 |
| Beta | 1.25 |
| 1 Month Change | 16.96% |
| 3 Month Change | 99.15% |
| 1 Year Change | 52.89% |
| 3 Year Change | -54.24% |
| 5 Year Change | -73.16% |
| Change since IPO | 305.62% |
Recent News & Updates
Seeking Alpha • Jun 22
Integra LifeSciences: New Beginning
Summary Integra LifeSciences specializes in neuro-related surgical devices and regenerative tissue technologies. The tissue reconstruction segment, featuring collagen-based products like Integra Skin and PriMatrix, is positioned as IART's primary future earnings driver. IART suffered significant earnings declines and a 75% share price drop due to FDA-related product recalls and operational lapses at its Boston facility. Signs of a turnaround are emerging, evidenced by a +46% YTD share price rebound following improved earnings performance. Read the full article on Seeking AlphaAnalysis Article • Jun 21
Integra LifeSciences Holdings (IART) Stock Could Be 34.9% Undervalued After Argus Upgrade
Integra LifeSciences Holdings (IART) moved into focus after Argus upgraded the stock, citing executive changes, resolved production issues and stronger profitability guidance following better than expected first quarter results. See our latest analysis for Integra LifeSciences Holdings. At a share price of $17.58, Integra LifeSciences Holdings has a 30 day share price return of 16.3% and a 90 day share price return of 96.6%. The 1 year total shareholder return of 51.6% contrasts with a 3 year...
Narrative Update • Jun 11
IART: Easing Operational Headwinds And Remediation Progress Will Support Repricing
Narrative Update Opening The updated analyst price target for Integra LifeSciences moves to $16 from $11. This reflects analysts' view that easing operational headwinds, improving supply and demand trends, and clearer remediation progress support modestly better assumptions for discount rate, revenue growth, profit margin, and future P/E.Recent updates
Seeking Alpha • Jun 22
Integra LifeSciences: New Beginning
Summary Integra LifeSciences specializes in neuro-related surgical devices and regenerative tissue technologies. The tissue reconstruction segment, featuring collagen-based products like Integra Skin and PriMatrix, is positioned as IART's primary future earnings driver. IART suffered significant earnings declines and a 75% share price drop due to FDA-related product recalls and operational lapses at its Boston facility. Signs of a turnaround are emerging, evidenced by a +46% YTD share price rebound following improved earnings performance. Read the full article on Seeking AlphaAnalysis Article • Jun 21
Integra LifeSciences Holdings (IART) Stock Could Be 34.9% Undervalued After Argus Upgrade
Integra LifeSciences Holdings (IART) moved into focus after Argus upgraded the stock, citing executive changes, resolved production issues and stronger profitability guidance following better than expected first quarter results. See our latest analysis for Integra LifeSciences Holdings. At a share price of $17.58, Integra LifeSciences Holdings has a 30 day share price return of 16.3% and a 90 day share price return of 96.6%. The 1 year total shareholder return of 51.6% contrasts with a 3 year...Narrative Update • Jun 11
IART: Easing Operational Headwinds And Remediation Progress Will Support Repricing
Narrative Update Opening The updated analyst price target for Integra LifeSciences moves to $16 from $11. This reflects analysts' view that easing operational headwinds, improving supply and demand trends, and clearer remediation progress support modestly better assumptions for discount rate, revenue growth, profit margin, and future P/E.Narrative Update • May 27
IART: Braintree Ramp And 2026 Execution Progress Will Support Repricing
Analysts lifted the fair value estimate for Integra LifeSciences Holdings to $27.00 from $25.00, reflecting updated assumptions around a slightly lower discount rate, modestly higher profit margins, and recent mixed price target changes across the Street. Analyst Commentary Recent Street research on Integra LifeSciences Holdings shows a mix of cautious and constructive views, with several firms adjusting price targets and ratings as they reassess the company after recent updates.Narrative Update • May 04
IART: Braintree Ramp And 2026 Milestones Will Support Repricing
Analysts have trimmed their price targets on Integra LifeSciences by a few dollars across several recent reports, reflecting more cautious views tied to inconsistent performance and updated assumptions for revenue, profit margins, and future P/E levels. Analyst Commentary Recent research reports on Integra LifeSciences have focused on resetting expectations for revenue trends, profit margins, and valuation multiples, with several firms adjusting their price targets to reflect updated models for the medical technology group as a whole.Narrative Update • Apr 19
IART: Braintree Ramp And Consistent 2026 Execution Will Drive Repricing
Analysts have trimmed their average 12 month price target for Integra LifeSciences Holdings by $1, citing recent target cuts from several firms and concerns around inconsistent performance, while still reflecting updated assumptions for slightly higher revenue growth, a wider profit margin and a lower future P/E multiple. Analyst Commentary Recent research on Integra LifeSciences Holdings has leaned cautious overall, with several firms trimming price targets and expressing concern about inconsistent execution.Narrative Update • Apr 04
IART: Braintree Ramp And Back Half 2026 Execution Will Drive Repricing
Analysts have lowered near term price targets on Integra LifeSciences Holdings to a range of $9 to $12, citing updated views after recent Q4 reports and an outlook weighted toward the second half of the year, tied to operational milestones such as the Braintree facility coming online. Analyst Commentary Recent Street research points to a mixed but constructive tone, with price targets consolidated in the $9 to $12 range and attention centered on execution milestones through the year.Narrative Update • Mar 21
IART: Braintree Ramp And Back Half Revenue Setup Will Drive Repricing
Analysts have trimmed their price targets on Integra LifeSciences, with recent moves to $9, $11 and $12 reflecting updated views on profit margins, higher assumed future P/E multiples, and a revenue outlook that is more heavily weighted toward the back half of the year. Analyst Commentary Recent research updates on Integra LifeSciences highlight a mix of caution on near term execution and recognition of potential catalysts that could influence how investors think about valuation, especially around profitability and revenue timing.Narrative Update • Mar 06
IART: Braintree Ramp And Margin Reset Will Support Long Term Upside
Analysts have trimmed their price targets on Integra LifeSciences to a range of about $11 to $12, citing updated expectations for revenue build through 2026, profit margins, and a lower assumed future P/E multiple. Analyst Commentary Recent Street updates on Integra LifeSciences keep the focus on valuation reset and execution risks, with price targets now clustered around $11 to $12.Narrative Update • Feb 20
IART: Improved Margins And Steady Outlook Will Support Long Term Upside
Analysts have reiterated a $25.00 price target for Integra LifeSciences Holdings, citing updated assumptions that reflect slightly higher modeled revenue growth, modestly better profit margins, and a marginally lower future P/E multiple. Valuation Changes Fair Value: $25.00 remains unchanged, with the updated assumptions still supporting the same implied value.Narrative Update • Feb 06
IART: Cardiac Surgery Clearance Will Support Long Term Upside Potential
Analysts have slightly adjusted their view on Integra LifeSciences Holdings, trimming the assumed future P/E from 33.67x to 32.61x while keeping fair value steady at $25.00. This reflects small tweaks to the discount rate, revenue growth expectations, and profit margin assumptions rather than a major shift in outlook.Analysis Article • Jan 29
Is It Time To Consider Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Integra LifeSciences Holdings Corporation ( NASDAQ:IART ), is not the largest company out there, but it saw significant...Narrative Update • Jan 22
IART: Cardiac Indication Expansion Will Support Long Term Upside Potential
Analysts have maintained their fair value estimate for Integra LifeSciences Holdings at US$25.00, indicating only minor adjustments in their long term assumptions for discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News FDA granted 510(k) clearance for Integra LifeSciences' CUSA Clarity Ultrasonic Surgical Aspirator System for specific cardiac surgery indications, including debridement of unwanted tissue in valve replacement and repair.Analysis Article • Jan 08
A Look At The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Key Insights Integra LifeSciences Holdings' estimated fair value is US$14.21 based on 2 Stage Free Cash Flow to Equity...Narrative Update • Jan 07
IART: Q3 Execution And New Cardiac Use Will Support Shares
Analysts recently nudged their price target on Integra LifeSciences to $15 from $13, citing expectations for "healthy" Q3 revenue and earnings across MedTech coverage. At the same time, they caution that limited new money in the sector could keep stock moves sensitive to positioning and any surprises around quarterly results.Narrative Update • Dec 15
IART: Stabilizing Earnings And New Cardiac Indication Will Support Shares
Analysts have modestly raised their price target on Integra LifeSciences, with our fair value estimate moving from about $29.78 to $25.00. This reflects expectations for healthy near term revenue and earnings, but is tempered by higher discount rates, slower projected revenue growth, and a lower future P/E multiple, even as long term margin assumptions improve.Analysis Article • Sep 06
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
Integra LifeSciences Holdings Corporation ( NASDAQ:IART ) shareholders would be excited to see that the share price has...Analysis Article • Jul 21
Is Integra LifeSciences Holdings (NASDAQ:IART) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • May 11
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) 28% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Integra LifeSciences Holdings Corporation ( NASDAQ:IART ) share price has...Analysis Article • Mar 27
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Looks Inexpensive But Perhaps Not Attractive Enough
Integra LifeSciences Holdings Corporation's ( NASDAQ:IART ) price-to-sales (or "P/S") ratio of 1x might make it look...Seeking Alpha • Mar 06
Integra LifeSciences: Light At The End Of The Tunnel, Or Another Oncoming Train? (Rating Upgrade)
Summary Integra LifeSciences had a rough 2024 as the company's quality control remediation efforts had a bigger than expected negative impact on results. Q4 '24 offered some stability with organic revenue growth and improved adjusted gross margins. 2025 guidance looks cautious, and a big cut to Q1 '25 expectations suggests that management may be pulling forward some of the lingering remediation costs. Integra LifeSciences is not yet past its quality control/remediation issues, but a new CEO gives the company a chance to turn the page and perhaps find areas of future improvement. Current valuation appears to price in significant risks, presenting a potential opportunity for contrarian investors. Read the full article on Seeking AlphaAnalysis Article • Jan 31
These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Extensively
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analysis Article • Nov 05
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise
Integra LifeSciences Holdings Corporation ( NASDAQ:IART ) shares have had a really impressive month, gaining 42% after...Analysis Article • Oct 24
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
While Integra LifeSciences Holdings Corporation ( NASDAQ:IART ) might not have the largest market cap around , it saw a...
New Narrative • Sep 24
LifeSciences' Strategic Moves To Boost Quality And Compliance For Long-term Profit Growth
Investing in compliance and quality improvements aims to enhance product supply reliability and support long-term revenue growth by meeting market demand.Analysis Article • Sep 08
Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S
With a price-to-sales (or "P/S") ratio of 0.9x Integra LifeSciences Holdings Corporation ( NASDAQ:IART ) may be sending...Analysis Article • Aug 21
Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Jul 01
At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?
Integra LifeSciences Holdings Corporation ( NASDAQ:IART ), is not the largest company out there, but it received a lot...Seeking Alpha • Jun 21
Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Summary Integra LifeSciences Holdings Corporation has continued to disappoint, with the company missing its own timelines for the reopening of the Boston manufacturing facility (a key piece of the Tissue Technologies business). Management's guidance for the second half of 2024 may be too optimistic, particularly given legitimate concerns about the company's ability to deliver on operational execution. The acquisition of ACCLARENT is a ho-hum move with minimal synergy, but some potential for growth leverage in overseas markets. With the pending departure of the CEO, Integra could get a fresh start in 2025 and that is badly needed; the shares trade at a seemingly low price, but a lot of work lies ahead. Read the full article on Seeking AlphaAnalysis Article • May 28
Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Integra LifeSciences Holdings fair value estimate is US$39.62...Shareholder Returns
| IART | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 6.6% | 3.9% | -2.5% |
| 1Y | 52.9% | -19.9% | 19.0% |
Return vs Industry: IART exceeded the US Medical Equipment industry which returned -19.9% over the past year.
Return vs Market: IART exceeded the US Market which returned 19% over the past year.
Price Volatility
| IART volatility | |
|---|---|
| IART Average Weekly Movement | 10.0% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IART has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IART's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | 4,427 | Stuart Essig | www.integralife.com |
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.
Integra LifeSciences Holdings Corporation Fundamentals Summary
| IART fundamental statistics | |
|---|---|
| Market cap | US$1.46b |
| Earnings (TTM) | -US$495.80m |
| Revenue (TTM) | US$1.64b |
0.9x
P/S Ratio-2.9x
P/E RatioIs IART overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IART income statement (TTM) | |
|---|---|
| Revenue | US$1.64b |
| Cost of Revenue | US$711.82m |
| Gross Profit | US$932.69m |
| Other Expenses | US$1.43b |
| Earnings | -US$495.80m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.37 |
| Gross Margin | 56.72% |
| Net Profit Margin | -30.15% |
| Debt/Equity Ratio | 179.1% |
How did IART perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 08:45 |
| End of Day Share Price | 2026/06/26 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Integra LifeSciences Holdings Corporation is covered by 28 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Matthew Taylor | Barclays |
| Charley Jones | Barrington Research Associates, Inc. |